Majority of Surveyed Physicians Oppose Automatic Substitution of Biosimilars
More than half think pharmacy-level substitution is inappropriate (Sept. 4)
BioTrends Research Group, located in Exton, Pa., reported on September 4 that surveyed specialist physicians in the U.S. and Europe are generally opposed to pharmacy-level automatic substitution of branded biologics for biosimilars.
More than half of 549 surveyed specialists (rheumatologists, gastroenterologists, endocrinologists, nephrologists, medical oncologists, and hematologist-oncologists) either said that automatic substitution is an overall bad idea, or they believed that it is only appropriate for specific biologic drug classes.
According to primary research findings, a significantly greater proportion of German physicians believe that automatic substitution is an overall bad idea, compared with surveyed physicians in the U.S. and France.
Physicians were most likely to believe that insulins are appropriate for automatic substitution, although opinions on which biologic drugs are appropriate significantly differed by specialty.
Approximately one quarter of the physicians thought that no biologics are appropriate for substitution.
For more information, visit the BioTrends Web site.